Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya3360510.26442/00403660.2019.09.000297Research ArticleThrombotic and hemorrhagic complications in atrial fibrillation patients, undergoing elective percutaneous coronary interventionKrivosheevaE Nlena-4ka@yandex.ruKropachevaE S-PanchenkoE P-SamkoA N-National Medical Research Center for Cardiology15092019919384616042020Copyright © 2019, Consilium Medicum2019Aim. To evaluate efficacy and safety of reduced dose of direct oral anticoagulants (DOACs) as part of triple antithrombotic therapy in AF patients, undergoing elective percutaneous coronary intervention (PCI), and to identify factors, associated with this strategy. Materials and methods. The study is a cohort analysis of AF patients with AF, who successfully underwent elective PCI and assigned DOACs as part of triple antithrombotic therapy (TAT).Influence of a reduced DOACs dose as a part of TAT on the frequency of thecomposite efficacy endpoint (acute coronary syndrome, ischemic stroke, venous thromboembolic events, cardiovascular death and angina pectoris aggravation/need for unplanned PCI) and safety endpoint (hemorrhagic complications BARC types 2-5) were assessed using the Log-Rank criterion. Results. The study included 124 pts (69.4% women, mean aged 69±8.2 years). Themedian total score CHA2DS2-VASc was 5, the median of the Charlson index composed 7. Half (52%) of AF patients with high risk of thrombotic events after elective PCI received reduced-DOACs dose. Median follow up period was 11.0 month. 17 adverse thrombotic events were recorded during this period, BARC 2-5 bleedings occurred in 27 patients. Reduced DOACs doses in AF patients undergoing PCI were associated with significant increase of thrombotic events during follow up period compared to patients received full DOACs doses (0.79 vs 0.93, Log-Rank p=0.0292). Patients, who received full and reduced DOAC doses, were comparable in the frequency of BARC 2-5 bleedings (0.78 vs 0.75, Log-Rank p=0.06742). Conclusions. The administration of a reduced DOACs dose as a part of TAT in patients with AF, who underwent PCI, was associated with significant increase in the incidence of all thrombotic events, compared to patients, who received full dose of anticoagulants. The number of hemorrhagic complications was comparable.direct oral anticoagulantstriple antithrombotic therapyatrial fibrillationpercutaneous coronary interventionsrisk of cardiovascular complicationsпрямые пероральные антикоагулянтытройная антитромботическая терапияфибрилляция предсердийчрескожные коронарные вмешательствариск сердечно сосудистых осложнений[Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw210][Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England J Medicine. 2009;361(12):1139-51. doi: 10. 1056/nejmoa0905561][Granger C, Alexander J, Mc Murray J, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England J Medicine. 2011;365(11):981-92. doi:10. 1056/nejmoa1107039][Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England J Medicine. 2011;365(10):883-91. doi: 10.1056/ nejmoa1009638][Giugliano R, Ruff C, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England J Medicine. 2013;369(22):2093-104. doi:10.1056/nejmoa1310907][Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК, РКО и АССХ 2017. Ссылка активна на 03.03.2019. https://vnoa.ru/upload/ edition_ june2017/4_fp.pdf][Steffel J, Verhamme P, Potpara T, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non - vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. doi: 10.1093/eurheartj/ehy136][Lip G, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155-79. doi: 10.1093/eurheartj/ehu298][Valgimigli M, Bueno H, Byrne R, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2017;39(3):213-60. doi: 10.1093/eurheartj/ehx419][Neumann F, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10. 1093/eurheartj/ehy394][Hart R, Pearce L, Aguilar M. Meta - analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146(12):857. doi: 10.7326/0003-4819-146-12-200706190-00007][Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. The Lancet. 2006;367(9526):1903-12. doi: 10.1016/s0140-6736(06)68845-4][Connolly S, Eikelboom J, Joyner C, et al. Apixaban in Patients with Atrial Fibrillation. New England J Medicine. 2011;364(9):806-17. doi: 10.1056/nejmoa 1007432][Bogacki P, Kabłak-Ziembicka A, Bryniarski K, et al. Triple anticoagulation therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention - real life assessment. Advances in Interventional Cardiology. 2016;4:303-13. doi: 10.5114/aic.2016.63629][Sørensen R, Hansen M, Abildstrom S, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. The Lancet. 2009;374(9706):1967-74. doi: 10.1016/s0140-6736 (09)61751-7][Hansen M, Sørensen R, Clausen M, et al. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. Arch Intern Med. 2010;170(16). doi: 10.1001/archinternmed.20 10.271][Angiolillo D, Goodman S, Bhatt D, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation. 2018;138(5):527-36. doi: 10. 1161/circulationaha.118.034722][Gibson C, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England J Medicine. 2016;375(25):2423-34. doi: 10.1056/nejmoa1611594][Cannon C, Bhatt D, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England J Medicine. 2017; 377(16):1513-24. doi: 10.1056/nejmoa1708454][Clemens A, Noack H, Ferreira J, Connolly S, Yusuf S, Lip G. Patient outcomes using the European label for dabigatran. Thromb Haemost. 2014;111(05):933-42. doi: 10.1160/th13-09-0734][Steinberg B, Shrader P, Pieper K, et al. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc. 2018;7(4). doi: 10.1161/jaha.117.007633][Панченко Е.П. Профилактика тромбоэмболических осложнений у пациентов с фибрилляцией предсердий после стентирования коронарных артерий. Атеротромбоз. 2015;(1):2-15. Ссылка активна на 03.03.2019. https://www.aterotromboz.ru/jour/article/view/2/2][Шахматова О.О., Панченко Е.П. Как снизить риск кровотечения при чрескожных коронарных вмешательствах у пациентов с фибрилляцией предсердий: уроки рандомизированных исследований и новые клинические рекомендации. Атеротромбоз. 2018;(1):93-106. doi: 10.21518/2307-1109-2018-1-93-106][Mehran R, Rao S, Bhatt D, et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation. 2011;123(23):2736-47. doi: 10.1161/ circulationaha.110.009449][Charlson M, Pompei P, Ales K, Mac Kenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8][Morisky D, Green L, Levine D. Concurrent and Predictive Validity of a Self - reported Measure of Medication Adherence. Med Care. 1986;24(1):67-74. doi: 10.1097/00005650-198601000-00007][McIntyre W, Conen D, Olshansky B, et al. Stroke - prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. Clin Cardiol. 2018;41(6):744-51. doi:10.1002/clc.22936][Steinberg B, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132-40. doi: 10.1016/j.ahj.2017.08.011][Piran S, Schulman S, Panju M, Pai M. Oral anticoagulant dosing, administration, and storage: a cross - sectional survey of Canadian health care providers. J Thromb Thrombolysis. 2017;45(1):180-5. doi: 10.1007/s11239-017-1585-y][Larock A, Mullier F, Sennesael A, et al. Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation. Annals of Pharmacotherapy. 2014;48(10):1258-68. doi: 10.1177/ 1060028014540868][Basaran O, Filiz Basaran N, Cekic E, et al. PRescriptiOn PattERns of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER study). Clinical and Applied Thrombosis/Hemostasis. 2015;23(4):384-91. doi: 10.1177/1076029615 614395][Pattullo C, Barras M, Tai B, Mc Kean M, Donovan P. New oral anticoagulants: appropriateness of prescribing in real - world setting. Intern Med J. 2016;46(7):812-8. doi: 10.1111/imj.13118][Belen E, Canbolat I, Bayyigit A, Helvaci A, Pusuroglu H, Kilickesmez K. A new gap in the novel anticoagulants’ era. Blood Coagulation & Fibrinolysis. 2015;26(7):793-7. doi: 10.1097/mbc.0000000000000349][Barra M, Fanikos J, Connors J, Sylvester K, Piazza G, Goldhaber S. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. Am J Med. 2016;129(11):1198-204. doi: 10.1016/j.amjmed.2016.05.041][Shrestha S, Baser O, Kwong W. Effect of Renal Function on Dosing of Non-Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation. Annals of Pharmacotherapy. 2017;52(2):147-53. doi: 10.1177/1060028017728295][Lavoie K, Turgeon M, Brais C, et al. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. J Atr Fibrillation. 2016;9(4). doi: 10.4022/jafib.1478][Ruiz Ortiz M, Muñiz J, Raña Míguez P, et al. Inappropriate doses of direct oral anticoagulants in real - world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. EP Europace. 2017;20(10):1577-83. doi: 10.1093/europace/eux316][Sato T, Aizawa Y, Fuse K, et al. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. J Stroke and Cerebrovascular Diseases. 2018;27(11):3280-8. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.028][Okumura Y, Yokoyama K, Matsumoto N, et al. Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. J Arrhythm. 2017;33(4):289-96. doi: 10.1016/j.joa.2016.11.003][Yamashita Y, Uozumi R, Hamatani Y, et al. Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients - Fushimi AF Registry. Circulation J. 2017;81(9):1278-85. doi: 10.1253/circj.cj-16-1337][Dewilde W, Oirbans T, Verheugt F, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open - label, randomised, controlled trial. The Lancet. 2013;381(9872):1107-15. doi: 10.1016/s0140-6736(12)62177-1][Abstract 10999: Outcomes Associated With Under-Dosing of Rivaroxaban for Management of Non-Valvular Atrial Fibrillation in Real World Clinical Setting From the XAPASS (Xarelto Post-Authorization Safety and Effectiveness Study in Japanese Patients With Atrial Fibrillation). Circulation. 2018;138:A 10999Ahajournals.org. https://www.ahajournals.org/doi/abs/10.1161/circ.138. suppl_1.10999?af=R][Undas A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost. 2014;112(07):32-42. doi: 10.1160/th14-01-0032][January C, Wann L, Alpert J, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. J Am Coll Cardiol. 2014;64(21):2246-80. doi: 10.1016/j.jacc.2014.03.021][Кропачева Е.С., Землянская О.А., Панченко Е.П., Добровольский А.Б., Кривошеева Е.Н. Безопасность длительной терапии варфарином: частота кровотечений и клинические предикторы их развития (результаты проспективного 15-летнего наблюдения). Атеротромбоз. 2017;(1):145-62. doi: 10.21518/ 2307-1109-2017-1-145-162]